Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New options for management

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Mar 03, 2021 7:47am

105 Views

Post# 32702784

RE:RE:RE:New options for management

Just wait till you see the amount of bonuses awarded to management and more specifically to Dubuc......

scarlet1967 wrote: I agree, they still get paid six figures so when the SP has been heavily outperformed by comps and the sector granting options almost looks like claiming victory, the problem is it doesn't feel like victory not for me not yet.

ANALIAS00 wrote: If I look at the SP, it seems they are the only one that recognize the work done to diserve all that money. For sure the market do not recognize it.

Thao977 wrote: Dubuc 73 333 Levesque 243 307 Marsolais 95 192 At $3,93 Huge amonth